Metabolic effects of moxonidine and other centrally acting antihypertensives

Diabetes, Obesity and Metabolism

Volumn 1, Issue 6, 1999, Pages 317-322

  Schachter, Michael ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Centrally acting hypertensives; Clonidine; Imidazoline receptors; Insulin resistance; Metabolic syndrome; Moxonidine

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; IMIDAZOLE DERIVATIVE; MOXONIDINE; OXAZOLE DERIVATIVE; RILMENIDINE;

ADRENERGIC SYSTEM; ANIMAL; DIABETES MELLITUS; DRUG EFFECT; HUMAN; HYPERTENSION; INSULIN RESISTANCE; METABOLISM; REVIEW; SYNDROME;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DIABETES COMPLICATIONS; HUMANS; HYPERTENSION; IMIDAZOLES; INSULIN RESISTANCE; METABOLISM; OXAZOLES; SYMPATHETIC NERVOUS SYSTEM; SYMPATHOLYTICS; SYNDROME;

EID: 0033224334     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.1999.00042.x     Document Type: Review

References (26)

1. Oster JR, Epstein M. Use of centrally acting sympatholytic agents in the management of hypertension. Arch Intern Med 1991; 151: 1638-1644.
2. 1) receptors as targets of centrally acting antihypertensives: moxonidine and rilmenidine. J Hypertens 1997; 15: 117-125.
3. Morris STW, Reid JL. Moxonidine: a review. J Human Hypertens 1997; 11: 629-635.
4. Julien C, Zhang ZQ, Barres C. How sympathetic tone maintains or alters blood pressure. Fundam Clin Pharmacol 1995; 9: 343-349.
5. Folkow B. Sympathetic nervous control of blood pressure: role in primary hypertension. Am J Hypertens 1989; 2 (Suppl): 103S-111S.
6. 1-imidazoline-binding site is a functional receptor mediating vasodepression via the ventral medulla. Am J Physiol 1997; 273: R1572-R1579.
7. Guyenet PG. Is the hypotensive effect of clonidine and related drugs due to imidazoline binding sites: Am J Physiol 1997; 273: R1580-R1584.
8. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. New Engl J Med 1996; 334: 374-381.
9. Brands MW, Hall JE, Keen HL. Is insulin resistance linked to hypertension? Clin Exp Pharmacol Physiol 1998; 25: 70-76.
10. Julius S, Jamerson K. Sympathetics, insulin resistance and coronary risk in hypertension: the 'chicken-and-egg' question. J Hypertens 1994; 12: 495-502.
11. Ernsberger P, Ishizuka T, Liu S, et al. Mechanism of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB). J Pharmacol Exp Ther 1999; 288: 139-147.
12. Henriksen EJ, Jacob S, Fogt DL, Youngblood EB, Gödicke J. Antihypertensive agent moxonidine enhances muscle glucose transport in insulin-resistant rats. Hypertension 1997; 30: 1560-1565.
13. Rösen P, Ohly P, Gleichmann H. Experimental benefit of moxonidine on glucose metabolism and insulin secretion in the fructose-fed rat. J Hypertens 1997; 15 (Suppl): S31-S38.
14. Penicaud L, Berthault MF, Morin J, Dubar M, Ktorza A, Ferre P. Rilmenidine normalizes fructose-induced insulin resistance and hypertension in rats. J Hypertens 1998; 16 (Suppl): S45-S49.
15. Lewis SJ, Dunlop M, Jarrott B. Serum glucose and insulin levels in normotensive (WKY) and spontaneously hypertensive (SH) rats during and after the cessation of continuous (10-day) clonidine infusion. J Pharm Pharmacol 1989; 41: 353-355.
16. Satia MC, Damani RR, Goyal RK. Beneficial effects of clonidine in streptozotocin-induced diabetes and DOCA-hypertensive rats. J Pharm Pharmacol 1997; 49: 1030-1035.
17. Hwang IS, Ho H, Hoffman BB, Reaven GM. Fructose-induced insulin resistance and hypertension in rats. Hypertension 1987; 10: 512-516.
18. Rocchini AP, Mao HZ, Babu K, Marker P, Rocchini AJ. Clonidine prevents insulin resistance and hypertension in obese dogs. Hypertension 1999; 33: 548-553.
19. Kaan EC, Bruckner R, Fröhly P, Tulp M, Shafer SG, Ziegler D. Effects of agmatine and moxonidine on glucose metabolism: an integrated approach towards pathophysiological mechanisms in cardiovascular metabolic disorders. Cardiovasc Risk Factors 1995; 5 (Suppl): 19-27.
20. Mpoy M, Vandeleene B, Ketelslegers JM, Lambert AE. Treatment of systemic hypertension in insulin-treated diabetes mellitus with rilmenidine. Am J Cardiol 1988; 61: 91D-94D.
21. Swislocki AL, Vestal RE, Reaven GM, Hoffman BB. Acute metabolic effects of clonidine and adenosine in man. Horm Metab Res 1993; 25: 90-95.
22. Nishina K, Mikawa K, Maekawa N, Shiga M, Obara H. Effects of oral clonidine premedication on plasma glucose and lipid homeostasis associated with exogenous glucose infusion in children. Anesthesiology 1998; 88: 922-927.
23. Nilssohn-Ehle P, Ekberg M, Fridstrom P, Ursing D, Lins LE. Lipoproteins and metabolic control in hypertensive type II diabetics treated with clonidine. Acta Med Scand 1988; 224: 131-134.
24. Giugliano D, Acampora R, Marfella R, et al. Hemodynamic and metabolic effects of transdermal clonidine in patients with hypertension and non-insulin-dependent diabetes mellitus. Am J Hypertens 1998; 11: 184-189.
25. Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-183.
26. 1 receptor agonist, moxonidine, inhibits insulin secretion from isolated rat islets of Langerhans. Eur J Pharmacol 1995; 284: 199-203.